Key Issue: USP–NF General Chapter <823> Radiopharmaceuticals for Positron Emission Tomography—Compounding
Original Posting: 24–Nov–2010; Last Update: 26–Apr–2013
- Scientific Liaison: Ravi Ravichandran (USP823@usp.org)
- Media: Theresa Laranang-Mutlu (email@example.com or 301-816-8167)
April 26, 2013: An article recently published by the Committee on Pharmacopeia associated with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) describes the impact of potential changes to the role of USP monographs for PET drugs after the sunset of the 1997 FDA Modernization Act requirements for PET drugs. In addition, the article contains recommendations for USP monographs for PET drugs that are currently not approved by the FDA. The article appears in the March issue (JNM, vol. 54, no 3, pp 472-475), and can be accessed here.
USP welcomes input from interested stakeholders regarding the monograph recommendations described in the article.
- October 26, 2012
The U.S. Pharmacopeial Convention (USP) is announcing the adoption of the revision of General Chapter <823> Radiopharmaceuticals for Positron Emission Tomography (PET)–Compounding in USP 35–NF 30, became official on May 1, 2012. The USP 35–NF 30 commentary, which is a summary of all the comments along with their disposition, can be found on the USP web site (commentary for <823> starts on page 8 of USP 35–NF Commentary.
USP has submitted a Citizen Petition to FDA to update the compendial reference to USP 35-NF 30 in the federal regulations on current good manufacturing practice (cGMP) for PET drugs (21 CFR § 212.5(b)).
- September 1, 2011
The U.S. Pharmacopeial Convention (USP) is announcing the adoption of the revision of General Chapter <823> Radiopharmaceuticals for Positron Emission Tomography (PET)-Compounding in USP 35–NF 30, which will be published in November 2011 and official on May 1, 2012. Once the official date is reached, the title of <823> will change to "Positron Emission Tomography Drugs for Compounding, Investigational, and Research Uses". The proposal was published in Pharmacopeial Forum (PF) 37(1)[Jan–Feb 2011] for the public review and comment period, which ended on March 31, 2011. USP received several comments from industry as well as the FDA. The Drugs for Positron Emission Tomography–Compounding Expert Panel reviewed all comments and recommended subsequent changes to the text to the General Chapters–Physical Analysis Expert Committee (GCPA) and the revision was approved by GCPA. The USP 35–NF 30 commentary, which is a summary of all the comments along with their disposition, will be posted on the USP web site in November 2011, coinciding with the publication. USP has initiated the process to petition FDA to update the compendial reference to USP 35–NF 30 in its regulation. Until the reference is amended, investigational and research PET drug manufacturers will still need to comply with General Chapter <823> of USP 32–NF 27 (2009) or the Code of Federal Regulations Title 21 Part 212 to meet CGMP requirements.
- March 25, 2011
On February 21, 2011 at 1:00pm EST/10:00am PST, USP hosted a live webinar where 75 participants from companies, universities and hospitals across the country shared their questions and concerns. This live event was recorded and is posted below along with the presentation slides and a document listing all the questions from the session with answers.
- November 24, 2010
The U.S. Pharmacopeial Convention (USP) is seeking input on a proposed revision of General Chapter <823> Radiopharmaceuticals for Positron Emission Tomography (PET)—Compounding in the U.S. Pharmacopeia–National Formulary (USP–NF). Input is being sought from practitioners involved in PET drug production and compounding in the fields of nuclear medicine, radiology, and diagnostic imaging and related areas. Read More
Originally published in 1998, General Chapter <823> describes requirements for the production and compounding of PET drugs, typically as injectable solutions in a multi-dose vial. Production is defined as the process of synthesis or formulation of a PET drug for investigational or research uses. Compounding is defined as the process of synthesis or formulation of a PET drug for use in pharmacy and medicine. Since the chapter's publication in 1998, technological, marketplace, and regulatory changes related to PET drugs have necessitated the chapter's revision.
In 2009, the U.S. Food and Drug Administration (FDA) published final regulations (the Final Rule) and an accompanying guidance document for PET Current Good Manufacturing Practices (CGMP). Once the FDA's Final Rule becomes effective on December 12, 2011, General Chapter <823> (as published in USP 32–NF 27) will officially constitute the minimum CGMP requirements for investigational and research PET drugs used in human subjects under an Investigational New Drug application or under the approval of a Radioactive Drug Research Committee. All other PET drugs will be subject to FDA's new CGMP requirements. It is important to note that the FDA Final Rule references General Chapter <823> in USP 32–NF 27. Once the current revision process for General Chapter <823> is completed and the chapter is published, USP will petition FDA to update the reference in its regulation. Until that is accomplished, investigational and research PET drug manufacturers will have to comply with the 1998 version of General Chapter <823> or the Code of Federal Regulations Title 21 Part 212 to meet CGMP requirements.
All comments to the revisions to Chapter <823> may be submitted to Dr. Ravi Ravichandran at USP823@usp.org by March 31, 2011.
Frequently Asked Questions
- Frequently Asked Questions (26–Jan–2011)
- Call for Candidates: USP Expert Panel on Radioactivity and Positron Emission Tomography (PET) Drugs (posted 26-Oct-2012)
- See March 25 update above for Webinar information.